STOCK TITAN

Utah Medical Products raises dividend to $0.315 a share

The new quarterly dividend is a 1.6% increase over the prior regular quarterly cash dividend.

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Utah Medical Products, Inc. approved a regular quarterly cash dividend of $0.315 per share. The dividend is payable January 5, 2027, to shareholders of record at the close of business December 17, 2026.

Positive

  • Minor pointQuarterly dividend increased 1.6% to $0.315 per share.

Negative

  • None.

Filing Explained

Utah Medical Products’ board approved a 1.6% increase in its regular quarterly cash dividend to $0.315 per share, increasing the stated per-share cash distribution to eligible holders.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Quarterly cash dividend $0.315 per share Regular quarterly dividend
Dividend increase 1.6% Over the prior regular quarterly cash dividend
Dividend record date December 17, 2026 Shareholders of record at the close of business
Dividend payment date January 5, 2027 Quarterly cash dividend payable date

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is UTMD's new quarterly dividend?

UTMD's regular quarterly cash dividend is $0.315 per share, a 1.6% increase over the prior regular quarterly cash dividend.

When is UTMD's dividend payable, and who qualifies?

The dividend is payable January 5, 2027, to shareholders of record at the close of business December 17, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0000706698 false 0000706698 2026-11-03 2026-11-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): November 3, 2026

 

 

UTAH MEDICAL PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

UTAH

 

000-12575

 

87-0342734

(State or other jurisdiction of

 

(Commission File Number)

 

(IRS Employer

incorporation or organization)

 

 

 

Identification No.)

 

 

 

 

 

7043 South 300 West

 

 

Midvale, Utah

 

84047

(Address of principal executive offices)

 

(Zip code)

 

 

 

Registrant’s telephone number, including area code:  

 

Phone: (801) 566-1200

 

 

 

n/a

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨




ITEM 8.01—OTHER EVENTS

 

On November 3, 2026, Utah Medical Products, Inc. announced that it is increasing its regular quarterly cash dividend. A dividend of $.315 per share is payable on January 5, 2027 to shareholders of record at the close of business on December 17, 2026.  A copy of the press release is attached hereto as Exhibit 99.1

 

 

ITEM 9.01—FINANCIAL STATEMENTS AND EXHIBITS

 

The following is filed as an exhibit to this report:  

 

Exhibit

Number*

 

 

Title of Document

 

 

Location

Item 99.1

 

Utah Medical Products, Inc. Increases Regular Quarterly Dividend

 

This filing

_______________________________________

*All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

UTAH MEDICAL PRODUCTS, INC.

 

 

 

 

 

 

 

 

 

Dated: November 3, 2026

By:

/s/ Kevin L. Cornwell

 

 

Kevin L. Cornwell,
Chief Executive Officer



EXHIBIT 99.1

 

Utah Medical Products, Inc. Increases Quarterly Dividend

 

Contact:  Brian KoopmanNovember 3, 2026 

(801) 566-1200

 

Salt Lake City, Utah - Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors has approved a quarterly cash dividend of thirty-one and one-half cents ($.315) per share of common stock payable on January 5, 2027 to stockholders of record at the close of business on December 17, 2026.  This is a 1.6% increase over the prior regular quarterly cash dividend.

 

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients.  For more information about Utah Medical Products, Inc., visit UTMD’s website at www.utahmed.com.

 

 

 

 


Filing Exhibits & Attachments

5 documents

Keep reading